Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCyte InternationalTPE:4178 -2.39%7 Current Ratio is 10.80 as of Mar. 2026, which is 2% above its 10-year median of 10.61. GuruFocus rates TPE:4178 with a GF Score™ of 7/100. The stock has 4 warning signs investors should review. Among 1,407 Biotechnology companies, StemCyte International ranks better than 79.53% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. StemCyte International's current ratio for the quarter that ended in Mar. 2026 was 10.80.
StemCyte International has a current ratio of 10.80. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for StemCyte International's Current Ratio or its related term are showing as below:
TPE:4178'
s Current Ratio Range Over the Past 10 Years
Min: 4.78 Med: 10.61 Max: 11.11
Current: 10.8
During the past 4 years, StemCyte International's highest Current Ratio was 11.11. The lowest was 4.78. And the median was 10.61.
TPE:4178's Current Ratio is ranked better than 79.53% of 1407
companies
in the Biotechnology industry
Industry Median: 3.83
vs TPE:4178: 10.80
StemCyte International (TPE:4178) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
StemCyte International Current Ratio Related Terms
StemCyte International Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4178 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, StemCyte International's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCyte International Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCyte International's Current Ratio distribution charts can be found below:
* The bar in red indicates where StemCyte International's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCyte International (TPE:4178) has a Current Ratio of 10.80 as of Mar. 2026. This is near median its historical median of 10.61. Over the past decade, StemCyte International's Current Ratio has ranged from 4.78 to 11.11. According to the industry distribution chart, StemCyte International ranks #288 out of 1407 companies in the Biotechnology industry, placing it in the top 20.5%.
Is StemCyte International's Current Ratio too high?
StemCyte International's current Current Ratio of 10.80 is near median its 10-year median of 10.61. Over the past 10 years, this metric has ranged from a low of 4.78 to a high of 11.11. The Biotechnology industry median Current Ratio is 3.83. StemCyte International's value of 10.80 is 182% above this industry median. Based on the distribution chart, StemCyte International ranks #288 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCyte International has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does StemCyte International's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCyte International ranks #288 out of 1407 companies for Current Ratio. This places StemCyte International in the top 21% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.83. StemCyte International's value of 10.80 is 182% above this benchmark. Historically, StemCyte International's own Current Ratio has ranged from 4.78 to 11.11 over the past decade. While the company's 10-year median is 10.61 vs. the industry median of 3.83, StemCyte International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,407 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCyte International's current Current Ratio of 10.80 is 182% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCyte International's current Current Ratio is 10.80, which is near median its own 10-year median of 10.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCyte International stock overvalued right now?
StemCyte International (TPE:4178) has a current Current Ratio of 10.80. The current Current Ratio is 10.80, which is near median its 10-year median of 10.61 and 182% above the Biotechnology industry median of 3.83. StemCyte International's overall GF Score™ is 7/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For StemCyte International (TPE:4178), the current Current Ratio is 10.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
StemCyte International Ltd is engaged in developing new stem cell drugs and test, process, and store umbilical cord blood (UCB)-related cells. The company's main operating activities are providing umbilical cord blood collection, processing and storage services. Its reportable segments are the United States, Taiwan, and Others. The majority of revenue is derived from the United States.
7GF Score
Get the complete analysis for TPE:4178
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4178 has been successfully added to your 
